{"transactions":[{"id":687064,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T18:12:12.000Z","date":"2026-08-14","kind":"gift","planned":false,"acquired":false,"shares":405880,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a gift of shares to the children of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 (\"Z3 Trust\").  The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-351801","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526351801/ownership.xml","form_type":"4"}},{"id":830932,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:07:54.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120214/ownership.xml","form_type":"4"}},{"id":830931,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:07:54.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":23742,"derivative":{"exercise_price":3.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120214/ownership.xml","form_type":"4"}},{"id":830930,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:07:54.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10362,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0001193125-26-120214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120214/ownership.xml","form_type":"4"}},{"id":830929,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:07:54.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":10362,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":10362,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0001193125-26-120214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120214/ownership.xml","form_type":"4"}},{"id":830928,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:07:54.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":99999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.596,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":99999},"source":{"system":"sec-edgar","filing":"0001193125-26-120214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120214/ownership.xml","form_type":"4"}},{"id":830927,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:07:54.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":99999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":99999,"derivative":{"exercise_price":3.91,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":99999},"source":{"system":"sec-edgar","filing":"0001193125-26-120214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120214/ownership.xml","form_type":"4"}},{"id":888251,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-23T21:11:13.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date."}],"balance_after":20400,"derivative":{"exercise_price":1.04,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-063984","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526063984/ownership.xml","form_type":"4"}},{"id":1135580,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:58:09.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":19111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":19111,"derivative":{"exercise_price":1.19,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":19111},"source":{"system":"sec-edgar","filing":"0000950170-25-077061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025077061/ownership.xml","form_type":"4"}},{"id":1173389,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:08:46.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":10523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":145538,"source":{"system":"sec-edgar","filing":"0000950170-25-053373","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025053373/ownership.xml","form_type":"4"}},{"id":1323008,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T23:33:29.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":9816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":135015,"source":{"system":"sec-edgar","filing":"0000950170-24-139793","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024139793/ownership.xml","form_type":"4"}},{"id":1349612,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:16:41.000Z","date":"2024-11-27","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":1.4,"value":2800.0,"ownership":{"direct":true},"balance_after":125199,"source":{"system":"sec-edgar","filing":"0000950170-24-131499","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024131499/ownership.xml","form_type":"4"}},{"id":1357432,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-20T21:11:58.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.01,"value":5050.0,"ownership":{"direct":true},"balance_after":123199,"source":{"system":"sec-edgar","filing":"0000950170-24-129248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024129248/ownership.xml","form_type":"4"}},{"id":1357431,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-20T21:11:58.000Z","date":"2024-11-18","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.9998,"value":19996.0,"ownership":{"direct":true},"balance_after":118199,"source":{"system":"sec-edgar","filing":"0000950170-24-129248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024129248/ownership.xml","form_type":"4"}},{"id":1472248,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T22:12:47.000Z","date":"2024-06-19","kind":"grant","planned":false,"acquired":true,"shares":64503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":64503,"derivative":{"exercise_price":2,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":64503},"source":{"system":"sec-edgar","filing":"0000950170-24-076399","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024076399/ownership.xml","form_type":"4"}},{"id":1653442,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-08T16:11:10.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.69,"exercise_date":"2024-02-03","expiration_date":"2033-02-03","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001209191-24-002992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919124002992/doc4.xml","form_type":"4"}},{"id":1653441,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-08T16:11:10.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":true,"shares":14150,"price":1.69,"value":23913.5,"ownership":{"direct":true},"balance_after":227439,"source":{"system":"sec-edgar","filing":"0001209191-24-002992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919124002992/doc4.xml","form_type":"4"}},{"id":1675414,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-20T00:32:12.000Z","date":"2024-01-18","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":19.1141,"value":1911410.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by Z3 Trust, for which the Reporting Person is a trustee."}],"balance_after":405880,"source":{"system":"sec-edgar","filing":"0000950170-24-005900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024005900/ownership.xml","form_type":"4"}},{"id":1860919,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option\n(right to buy)","published_at":"2023-06-10T00:57:24.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":23742,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0000899243-23-015321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323015321/doc4.xml","form_type":"4"}},{"id":2028429,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T16:48:23.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date."}],"balance_after":14150,"derivative":{"exercise_price":1.69,"expiration_date":"2033-02-03","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001209191-23-007560","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123007560/doc4.xml","form_type":"4"}},{"id":2092252,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-08T17:09:18.000Z","date":"2022-12-07","kind":"purchase","acquired":true,"shares":21202,"price":1.3,"value":27562.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $1.28 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"27,551 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":154618,"source":{"system":"sec-edgar","filing":"0001209191-22-060377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919122060377/doc4.xml","form_type":"4"}},{"id":2270596,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:11:21.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":10362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from March 25, 2022."}],"balance_after":10362,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0000899243-22-018273","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018273/doc4.xml","form_type":"4"}},{"id":2270380,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-16T16:24:11.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":743,"price":1.61,"value":1196.23,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"55,102 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":133416,"source":{"system":"sec-edgar","filing":"0001209191-22-029135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919122029135/doc4.xml","form_type":"4"}},{"id":2273552,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T16:35:17.000Z","date":"2022-05-11","kind":"purchase","acquired":true,"shares":1000,"price":1.7,"value":1700.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"55,102 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":132673,"source":{"system":"sec-edgar","filing":"0001209191-22-028574","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919122028574/doc4.xml","form_type":"4"}},{"id":2273551,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-12T16:35:17.000Z","date":"2022-05-10","kind":"purchase","acquired":true,"shares":49406,"price":1.89,"value":93377.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $1.67 to $2.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"55,102 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":131673,"source":{"system":"sec-edgar","filing":"0001209191-22-028574","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919122028574/doc4.xml","form_type":"4"}},{"id":2313131,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-04-01T00:15:34.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":98199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":98199},"source":{"system":"sec-edgar","filing":"0000899243-22-012992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012992/doc4.xml","form_type":"4"}},{"id":2313130,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:34.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":98199,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."}],"balance_after":98199,"source":{"system":"sec-edgar","filing":"0000899243-22-012992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012992/doc4.xml","form_type":"4"}},{"id":2366632,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-01T22:15:06.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":25000,"derivative":{"exercise_price":5.9,"expiration_date":"2032-02-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-014161","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919122014161/doc4.xml","form_type":"4"}},{"id":2366631,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-01T22:15:06.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":60700,"source":{"system":"sec-edgar","filing":"0001209191-22-014161","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919122014161/doc4.xml","form_type":"4"}},{"id":2374764,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-24T17:03:24.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on February 22, 2023, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date."}],"balance_after":14150,"derivative":{"exercise_price":5.96,"expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0000899243-22-007653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924322007653/doc4.xml","form_type":"4"}},{"id":2457897,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-28T18:24:18.000Z","date":"2021-12-28","kind":"purchase","acquired":true,"shares":601,"price":9.85,"value":5919.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.81 to $9.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":82267,"source":{"system":"sec-edgar","filing":"0000899243-21-049973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321049973/doc4.xml","form_type":"4"}},{"id":2457896,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-28T18:24:18.000Z","date":"2021-12-27","kind":"purchase","acquired":true,"shares":99,"price":10.18,"value":1007.82,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":81666,"source":{"system":"sec-edgar","filing":"0000899243-21-049973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321049973/doc4.xml","form_type":"4"}},{"id":2457895,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-28T18:24:18.000Z","date":"2021-12-27","kind":"purchase","acquired":true,"shares":200,"price":9.97,"value":1994.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":81567,"source":{"system":"sec-edgar","filing":"0000899243-21-049973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321049973/doc4.xml","form_type":"4"}},{"id":2457894,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-28T18:24:18.000Z","date":"2021-12-23","kind":"purchase","acquired":true,"shares":200,"price":9.87,"value":1974.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":81367,"source":{"system":"sec-edgar","filing":"0000899243-21-049973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321049973/doc4.xml","form_type":"4"}},{"id":2462454,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T18:06:55.000Z","date":"2021-12-17","kind":"purchase","acquired":true,"shares":200,"price":9.88,"value":1976.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"84,523 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":81167,"source":{"system":"sec-edgar","filing":"0000899243-21-049198","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321049198/doc4.xml","form_type":"4"}},{"id":2470619,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-17T01:01:33.000Z","date":"2021-12-15","kind":"purchase","acquired":true,"shares":2000,"price":3.155,"value":6310.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Please see the section titled \"Remarks\" below for additional information."}],"balance_after":196547,"source":{"system":"sec-edgar","filing":"0001562180-21-007737","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000156218021007737/primarydocument.xml","form_type":"4"}},{"id":2470618,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-12-17T01:01:33.000Z","date":"2021-12-14","kind":"purchase","acquired":true,"shares":10000,"price":3.2689,"value":32689.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":194547,"source":{"system":"sec-edgar","filing":"0001562180-21-007737","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000156218021007737/primarydocument.xml","form_type":"4"}},{"id":2471626,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T20:09:26.000Z","date":"2021-12-15","kind":"purchase","acquired":true,"shares":1700,"price":11.12,"value":18904.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $10.95 to $11.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"84,523 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":80967,"source":{"system":"sec-edgar","filing":"0000899243-21-048432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321048432/doc4.xml","form_type":"4"}},{"id":2471625,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T20:09:26.000Z","date":"2021-12-15","kind":"purchase","acquired":true,"shares":2000,"price":10.47,"value":20940.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.95 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"84,523 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest."}],"balance_after":79267,"source":{"system":"sec-edgar","filing":"0000899243-21-048432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321048432/doc4.xml","form_type":"4"}},{"id":2500522,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:12:32.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":3222,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":115.53,"underlying":"Common Stock","underlying_shares":3222},"source":{"system":"sec-edgar","filing":"0001104659-21-142280","document":"tm2133601-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142280/tm2133601-13_4seq1.xml","form_type":"4"}},{"id":2500521,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:12:32.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":8185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":52.99,"underlying":"Common Stock","underlying_shares":8185},"source":{"system":"sec-edgar","filing":"0001104659-21-142280","document":"tm2133601-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142280/tm2133601-13_4seq1.xml","form_type":"4"}},{"id":2500520,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:12:32.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.64,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-142280","document":"tm2133601-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142280/tm2133601-13_4seq1.xml","form_type":"4"}},{"id":2500519,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:12:32.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.2,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-21-142280","document":"tm2133601-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142280/tm2133601-13_4seq1.xml","form_type":"4"}},{"id":2500518,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:12:32.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":40.61,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-142280","document":"tm2133601-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142280/tm2133601-13_4seq1.xml","form_type":"4"}},{"id":2500517,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:12:32.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":30.17,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-142280","document":"tm2133601-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142280/tm2133601-13_4seq1.xml","form_type":"4"}},{"id":2500516,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:12:32.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":27.97,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-21-142280","document":"tm2133601-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142280/tm2133601-13_4seq1.xml","form_type":"4"}},{"id":2500515,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T09:12:32.000Z","date":"2021-11-19","kind":"other","acquired":false,"shares":34499,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-142280","document":"tm2133601-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142280/tm2133601-13_4seq1.xml","form_type":"4"}},{"id":2655850,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-06-24T20:54:15.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":200000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":58671},"source":{"system":"sec-edgar","filing":"0000899243-21-025827","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321025827/doc4.xml","form_type":"4"}},{"id":2655849,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-24T20:54:15.000Z","date":"2021-06-22","kind":"exercise","acquired":true,"shares":58671,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein."}],"balance_after":58671,"source":{"system":"sec-edgar","filing":"0000899243-21-025827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000089924321025827/doc4.xml","form_type":"4"}},{"id":2667062,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-17T00:07:50.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On June 14, 2021, the Reporting Person was granted 36,000 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in such year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":36000,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001562180-21-004331","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000156218021004331/primarydocument.xml","form_type":"4"}},{"id":2667061,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T00:07:50.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":45953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 14, 2021, the Reporting Person was granted an option to purchase 45,953 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the \"Plan\"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":45953,"derivative":{"exercise_price":5,"expiration_date":"2031-06-14","underlying":"Ordinary Shares","underlying_shares":45953},"source":{"system":"sec-edgar","filing":"0001562180-21-004331","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000156218021004331/primarydocument.xml","form_type":"4"}},{"id":2757380,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-04-05T20:27:17.000Z","date":"2021-04-05","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant."}],"balance_after":0,"derivative":{"exercise_price":24.11,"expiration_date":"2023-12-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-21-004227","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004227/edgar.xml","form_type":"4"}},{"id":2757379,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:27:17.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":1100,"price":142.27,"value":156497.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.07 to $142.57 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":34499,"source":{"system":"sec-edgar","filing":"0001179110-21-004227","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004227/edgar.xml","form_type":"4"}},{"id":2757378,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:27:17.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":2152,"price":141.28,"value":304034.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.01 to $142.00 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":35599,"source":{"system":"sec-edgar","filing":"0001179110-21-004227","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004227/edgar.xml","form_type":"4"}},{"id":2757377,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:27:17.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":6748,"price":140.31,"value":946811.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.01 to $140.99 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":37751,"source":{"system":"sec-edgar","filing":"0001179110-21-004227","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004227/edgar.xml","form_type":"4"}},{"id":2757376,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T20:27:17.000Z","date":"2021-04-05","kind":"exercise","acquired":true,"shares":10000,"price":24.11,"value":241100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":44499,"source":{"system":"sec-edgar","filing":"0001179110-21-004227","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004227/edgar.xml","form_type":"4"}},{"id":2760801,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-04-02T18:08:27.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant."}],"balance_after":10000,"derivative":{"exercise_price":24.11,"expiration_date":"2023-12-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-21-004122","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004122/edgar.xml","form_type":"4"}},{"id":2760800,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:08:27.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1600,"price":135.67,"value":217072.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.64 to $135.73 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4."}],"balance_after":34499,"source":{"system":"sec-edgar","filing":"0001179110-21-004122","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004122/edgar.xml","form_type":"4"}},{"id":2760799,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:08:27.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1700,"price":135.22,"value":229874.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.62 to $135.51 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":36099,"source":{"system":"sec-edgar","filing":"0001179110-21-004122","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004122/edgar.xml","form_type":"4"}},{"id":2760798,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:08:27.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":6596,"price":134.27,"value":885644.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.62 to $134.61 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":37799,"source":{"system":"sec-edgar","filing":"0001179110-21-004122","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004122/edgar.xml","form_type":"4"}},{"id":2760797,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:08:27.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":104,"price":132.61,"value":13791.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.57 to $133.50 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":44395,"source":{"system":"sec-edgar","filing":"0001179110-21-004122","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004122/edgar.xml","form_type":"4"}},{"id":2760796,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-02T18:08:27.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":10000,"price":24.11,"value":241100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":44499,"source":{"system":"sec-edgar","filing":"0001179110-21-004122","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021004122/edgar.xml","form_type":"4"}},{"id":2827649,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-02T02:07:32.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":16400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended."}],"balance_after":16400,"derivative":{"exercise_price":11.19,"expiration_date":"2031-02-24","underlying":"Common Stock","underlying_shares":16400},"source":{"system":"sec-edgar","filing":"0001209191-21-015514","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919121015514/doc4.xml","form_type":"4"}},{"id":2827648,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-02T02:07:32.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\"). The RSUs will fully vest on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP, as amended\")), through such date and subject to acceleration as provided in the 2018 EIP, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,000 shares of common stock issuable upon settlement of RSUs subject to Reporting Person's May 18, 2020 RSU grant that will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the Issuer's 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended."}],"balance_after":48200,"source":{"system":"sec-edgar","filing":"0001209191-21-015514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919121015514/doc4.xml","form_type":"4"}},{"id":2885158,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-02-02T19:00:29.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":3222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":3222,"derivative":{"exercise_price":115.53,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":3222},"source":{"system":"sec-edgar","filing":"0001179110-21-001114","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001114/edgar.xml","form_type":"4"}},{"id":2885157,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T19:00:29.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":1622,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":34499,"source":{"system":"sec-edgar","filing":"0001179110-21-001114","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001114/edgar.xml","form_type":"4"}},{"id":3001782,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-23T00:03:29.000Z","date":"2020-10-21","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option granted to the Reporting Person is fully vested as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":3.4,"expiration_date":"2020-11-11","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001562180-20-006417","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000156218020006417/primarydocument.xml","form_type":"4"}},{"id":3001781,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-10-23T00:03:29.000Z","date":"2020-10-21","kind":"exercise","acquired":true,"shares":100000,"price":3.4,"value":340000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Please see the section titled \"Remarks\" below for additional information."}],"balance_after":184547,"source":{"system":"sec-edgar","filing":"0001562180-20-006417","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000156218020006417/primarydocument.xml","form_type":"4"}},{"id":3082941,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-07-16T00:09:17.000Z","date":"2020-07-13","kind":"grant","acquired":true,"shares":27191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 13, 2020, the Reporting Person was granted 27,191 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of July 13, 2020 or (ii) the Issuer's annual general meeting of shareholders in such year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":27191,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":27191},"source":{"system":"sec-edgar","filing":"0001562180-20-005127","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000156218020005127/primarydocument.xml","form_type":"4"}},{"id":3082940,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-16T00:09:17.000Z","date":"2020-07-13","kind":"grant","acquired":true,"shares":34805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 13, 2020, the Reporting Person was granted an option to purchase 34,805 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the \"Plan\"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of July 13, 2020 or (ii) the Issuer's annual general meeting of shareholders in 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":34805,"derivative":{"exercise_price":6.62,"expiration_date":"2030-07-13","underlying":"Ordinary Shares","underlying_shares":34805},"source":{"system":"sec-edgar","filing":"0001562180-20-005127","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000156218020005127/primarydocument.xml","form_type":"4"}},{"id":3125209,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-03T20:30:52.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended."}],"balance_after":20000,"derivative":{"exercise_price":10.46,"expiration_date":"2030-05-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-034033","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120034033/doc4a.xml","form_type":"4/A","original_submission_date":"2020-05-20"}},{"id":3125208,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-03T20:30:52.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP, as amended\")), through such date and subject to acceleration as provided in the 2018 EIP, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020.  Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020.  Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-20-034033","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120034033/doc4a.xml","form_type":"4/A","original_submission_date":"2020-05-20"}},{"id":3141426,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-20T21:22:28.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date."}],"balance_after":15000,"derivative":{"exercise_price":10.46,"expiration_date":"2030-05-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-030966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120030966/doc4.xml","form_type":"4"}},{"id":3141425,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-20T21:22:28.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":32500,"source":{"system":"sec-edgar","filing":"0001209191-20-030966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120030966/doc4.xml","form_type":"4"}},{"id":3201141,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-19T21:00:15.000Z","date":"2020-03-17","kind":"purchase","acquired":true,"shares":5000,"price":4.99,"value":24950.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,500 shares of common stock subject to restricted stock units (\"RSUs\") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-20-020303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120020303/doc4.xml","form_type":"4"}},{"id":3211778,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-13T21:41:46.000Z","date":"2020-03-13","kind":"purchase","acquired":true,"shares":5000,"price":5.67,"value":28350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,500 shares of common stock subject to restricted stock units (\"RSUs\") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-20-019005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120019005/doc4.xml","form_type":"4"}},{"id":3211777,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-13T21:41:46.000Z","date":"2020-03-12","kind":"purchase","acquired":true,"shares":15000,"price":6.31,"value":94650.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,500 shares of common stock subject to restricted stock units (\"RSUs\") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-20-019005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919120019005/doc4.xml","form_type":"4"}},{"id":3302767,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-01-24T17:59:15.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":8185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":8185,"derivative":{"exercise_price":52.99,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":8185},"source":{"system":"sec-edgar","filing":"0001179110-20-000782","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000782/edgar.xml","form_type":"4"}},{"id":3302766,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T17:59:15.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":1377,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32877,"source":{"system":"sec-edgar","filing":"0001179110-20-000782","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000782/edgar.xml","form_type":"4"}},{"id":3314419,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-01-09T16:36:05.000Z","date":"2020-01-07","kind":"exercise","acquired":false,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant."}],"balance_after":0,"derivative":{"exercise_price":3.88,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001179110-20-000436","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000436/edgar.xml","form_type":"4"}},{"id":3314418,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-09T16:36:05.000Z","date":"2020-01-07","kind":"exercise","acquired":true,"shares":18750,"price":3.88,"value":72750.0,"ownership":{"direct":true},"balance_after":31500,"source":{"system":"sec-edgar","filing":"0001179110-20-000436","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911020000436/edgar.xml","form_type":"4"}},{"id":3324726,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-04T02:30:33.000Z","date":"2020-01-03","kind":"exercise","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option granted to the Reporting Person is fully vested as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":100000,"derivative":{"exercise_price":3.4,"expiration_date":"2020-11-11","underlying":"Ordinary Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-20-001469","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919120001469/doc4.xml","form_type":"4"}},{"id":3324725,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-01-04T02:30:33.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":300000,"price":20.9429,"value":6282870.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"security","element":"securityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.71 to $21.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Please see the section title \"Remarks\" below for additional information."}],"balance_after":84547,"source":{"system":"sec-edgar","filing":"0001209191-20-001469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919120001469/doc4.xml","form_type":"4"}},{"id":3324724,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-01-04T02:30:33.000Z","date":"2020-01-03","kind":"exercise","acquired":true,"shares":300000,"price":3.4,"value":1020000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"security","element":"securityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":384547,"source":{"system":"sec-edgar","filing":"0001209191-20-001469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919120001469/doc4.xml","form_type":"4"}},{"id":3337493,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-19T01:05:17.000Z","date":"2019-12-16","kind":"exercise","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option granted to the Reporting Person is fully vested as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":138542,"derivative":{"exercise_price":9,"expiration_date":"2021-10-20","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-061213","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119061213/doc4.xml","form_type":"4"}},{"id":3337492,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-12-19T01:05:17.000Z","date":"2019-12-16","kind":"sale","acquired":false,"shares":100000,"price":25.8338,"value":2583380.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"security","element":"securityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.80 to $25.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Please see the section title \"Remarks\" below for additional information."}],"balance_after":84547,"source":{"system":"sec-edgar","filing":"0001209191-19-061213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119061213/doc4.xml","form_type":"4"}},{"id":3337491,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-12-19T01:05:17.000Z","date":"2019-12-16","kind":"exercise","acquired":true,"shares":100000,"price":9,"value":900000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"security","element":"securityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":184547,"source":{"system":"sec-edgar","filing":"0001209191-19-061213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119061213/doc4.xml","form_type":"4"}},{"id":3467075,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-06T01:00:18.000Z","date":"2019-07-05","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option granted to the Reporting Person is fully vested as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":238542,"derivative":{"exercise_price":9,"expiration_date":"2021-10-20","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-041364","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119041364/doc4.xml","form_type":"4"}},{"id":3467074,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-07-06T01:00:18.000Z","date":"2019-07-05","kind":"sale","acquired":false,"shares":100000,"price":23.8158,"value":2381580.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"security","element":"securityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $23.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Please see the section title \"Remarks\" below for additional information."}],"balance_after":84547,"source":{"system":"sec-edgar","filing":"0001209191-19-041364","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119041364/doc4.xml","form_type":"4"}},{"id":3467073,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-07-06T01:00:18.000Z","date":"2019-07-05","kind":"exercise","acquired":true,"shares":100000,"price":9,"value":900000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"security","element":"securityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Please see the section title \"Remarks\" below for additional information."}],"balance_after":184547,"source":{"system":"sec-edgar","filing":"0001209191-19-041364","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119041364/doc4.xml","form_type":"4"}},{"id":3483270,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-21T00:05:58.000Z","date":"2019-06-18","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option granted to the Reporting Person is fully vested as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":400000,"derivative":{"exercise_price":3.4,"expiration_date":"2020-11-11","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-038330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119038330/doc4.xml","form_type":"4"}},{"id":3483269,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-06-21T00:05:58.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":100000,"price":19.0209,"value":1902090.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"security","element":"securityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.98 to $19.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Please see the section title \"Remarks\" below for additional information."}],"balance_after":84547,"source":{"system":"sec-edgar","filing":"0001209191-19-038330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119038330/doc4.xml","form_type":"4"}},{"id":3483268,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-06-21T00:05:58.000Z","date":"2019-06-18","kind":"exercise","acquired":true,"shares":100000,"price":3.4,"value":340000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"security","element":"securityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Please see the section title \"Remarks\" below for additional information."}],"balance_after":184547,"source":{"system":"sec-edgar","filing":"0001209191-19-038330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119038330/doc4.xml","form_type":"4"}},{"id":3487542,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:08:42.000Z","date":"2019-06-14","kind":"purchase","acquired":true,"shares":5000,"price":38.05,"value":190250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.03 to $38.05 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":12750,"source":{"system":"sec-edgar","filing":"0001179110-19-007787","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911019007787/edgar.xml","form_type":"4"}},{"id":3493227,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-12T21:13:10.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date."}],"balance_after":15000,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-036449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119036449/doc4.xml","form_type":"4"}},{"id":3493226,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-12T21:13:10.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of restricted stock units (\"RSUs\"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-19-036449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919119036449/doc4.xml","form_type":"4"}},{"id":3517474,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-05-22T00:12:30.000Z","date":"2019-05-20","kind":"grant","acquired":true,"shares":7428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On May 20, 2019, the Reporting Person was granted 7,428 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in such year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":7428,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":7428},"source":{"system":"sec-edgar","filing":"0001209191-19-031866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119031866/doc4.xml","form_type":"4"}},{"id":3517473,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-22T00:12:30.000Z","date":"2019-05-20","kind":"grant","acquired":true,"shares":9658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 20, 2019, the Reporting Person was granted an option to purchase 9,658 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the \"Plan\"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":9658,"derivative":{"exercise_price":16.83,"expiration_date":"2029-05-20","underlying":"Ordinary Shares","underlying_shares":9658},"source":{"system":"sec-edgar","filing":"0001209191-19-031866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119031866/doc4.xml","form_type":"4"}},{"id":3639923,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-23T02:34:59.000Z","date":"2019-02-22","kind":"exercise","acquired":false,"shares":36875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option granted to the Reporting Person is fully vested as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":8.1,"expiration_date":"2023-01-02","underlying":"Ordinary Shares","underlying_shares":36875},"source":{"system":"sec-edgar","filing":"0001209191-19-012808","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119012808/doc4.xml","form_type":"4"}},{"id":3639922,"issuer":{"id":5970,"kind":"organization","name":"AMARIN CORP PLC\\UK"},"owners":[{"id":23401,"kind":"person","name":"Zakrzewski Joseph S","position":1,"cik":"0001331852","reported_name":"Zakrzewski Joseph S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-23T02:34:59.000Z","date":"2019-02-22","kind":"exercise","acquired":false,"shares":143750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option granted to the Reporting Person is fully vested as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":8.86,"expiration_date":"2022-02-01","underlying":"Ordinary Shares","underlying_shares":143750},"source":{"system":"sec-edgar","filing":"0001209191-19-012808","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/897448/000120919119012808/doc4.xml","form_type":"4"}}],"next_cursor":"2019-02-23T02:34:59.000000Z,3639922"}